EPO-TEK 301-2 PMF SYRINGE

Hazard statements (CLP)

H314, H317, H318, H411

Code

Statements

H314

Causes severe skin burns and eye damage

SECTION 2: Hazards identification

Adverse physicochemical, human health and environmental effects

Causes severe skin burns and eye damage. May cause an allergic skin reaction. Causes serious eye damage. Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling

Hazard pictograms

GHS05 GHS07 GHS09

Signal word

Danger

Contains

Polyoxypropylenediamine; bis-[4-(2,3-epoxipropoxi)phenyl]propane

Hazard statements

H314 - Causes severe skin burns and eye damage. H317 - May cause an allergic skin reaction. H411 - Toxic to aquatic life with long lasting effects.

Precautionary statements

P260 - Do not breathe dust/fume/gas/mist/vapours/spray. P264 - Wash hands, forearms and face thoroughly after handling. P272 - Contaminated work clothing should not be allowed out of the workplace. P273 - Avoid release to the environment. P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection. P301+P330+P331 - IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.

Other hazards which do not result in classification

Harmful dust may be released during cutting, milling or grinding process. Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII Component Polyoxypropylenediamine (9046-10-0) This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII bis-[4-(2,3-epoxipropoxi)phenyl]propane (1675-54-3) This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 % Component bis-[4-(2,3-epoxipropoxi)phenyl]propane(1675-54-3) The substance is not included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605